Malignant neoplasm of small intestine
Chapter 2:Neoplasms
ICD-10 C17 is a billable code used to indicate a diagnosis of malignant neoplasm of small intestine.
Malignant neoplasms of the small intestine are rare tumors that can arise from various types of cells within the small intestine, including adenocarcinomas, lymphomas, and neuroendocrine tumors. These tumors can present with a variety of symptoms, including abdominal pain, weight loss, gastrointestinal bleeding, and obstruction. The small intestine is divided into three sections: the duodenum, jejunum, and ileum, and malignancies can occur in any of these areas. Diagnosis often involves imaging studies such as CT scans or MRIs, endoscopy, and biopsy to confirm malignancy. Due to the rarity of these tumors, they can be challenging to diagnose, and symptoms may be nonspecific, leading to delays in treatment. The prognosis varies significantly based on the type of tumor, stage at diagnosis, and the patient's overall health. Treatment typically involves surgical resection, chemotherapy, and/or radiation therapy, depending on the tumor type and stage.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of small intestine tumors, staging, and follow-up care.
Ensure accurate coding of tumor type and stage; multidisciplinary documentation is crucial.
Endoscopy reports, biopsy results, and imaging studies.
Evaluation of gastrointestinal symptoms leading to diagnosis of malignancy.
Documentation must clearly differentiate between benign and malignant findings.
Used in cases of malignant neoplasm requiring surgical intervention.
Operative reports detailing the procedure and findings.
Oncology and surgery documentation must align for accurate coding.
The most common types include adenocarcinomas, lymphomas, and neuroendocrine tumors. Each type has distinct characteristics and treatment protocols.
Coders should ensure detailed documentation of the tumor type, location, and stage, and be familiar with the specific coding guidelines for each type of malignancy.
